Physician profile
William C Simon
NPI 1952352007
$14,154.11
in general payments reported to CMS, 2019-2025
65 companies · $1,917 in 2025
The $1,917 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $994 · 2020: $1,517 · 2021: $2,645 · 2022: $2,590 · 2023: $2,640 · 2024: $1,853 · 2025: $1,917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,360 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,359.51 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,147.73 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $1,668.45 | 2019-2025 | Linzess, Qulipta, Viberzi |
| Astrazeneca Pharmaceuticals Lp | $1,436.39 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $1,051.31 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $870.57 | 2019-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $727.18 | 2019-2025 | |
| Astellas Pharma US INC | $486.17 | 2019-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $479.41 | 2020-2024 | Bexsero, Trelegy Ellipta, Arexvy |
| Amarin Pharma, INC. | $433.05 | 2019-2022 | |
| Abbott Laboratories | $301.60 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Vanda Pharmaceuticals INC. | $235.30 | 2020-2025 | Fanapt, Hetlioz |
| Jazz Pharmaceuticals INC. | $231.31 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $215.79 | 2021-2025 | |
| Sanofi Pasteur INC. | $185.28 | 2021-2024 | |
| Idorsia Pharmaceuticals US INC | $184.15 | 2023-2024 | Quviviq |
Show all 61 companies
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Simon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.